Abingworth, Bain Capital Life Sciences, and Venrock Healthcare led a $180m Series A round in Timberlyne Therapeutics.

Abingworth, Bain Capital Life Sciences, and Venrock Healthcare led a $180m Series A round in Timberlyne Therapeutics, a US-based clinical-stage biopharmaceutical company specializing in the development of monoclonal antibody therapies for autoimmune diseases and cancers, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP, and 3H Health Investment.